Sign in
CompletedNo phase

Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity

Key facts

Who runs it
Zhongshan Hospital (Xiamen), Fudan University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
42 people enrolled
Started
31 Jan 2024
Ended
28 Feb 2025
Type of study
Observational, 4 groups
Treatments tested
  • 13C-Urea Breath Test
  • Hydrogen-Methane Breath Test
Record updated
25 March 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Age from 18 to 65 years
  • All enrolled patients underwent both the 13C-urea breath test (13C-UBT) and hydrogen-methane breath test (HMBT)

Who cannot take part

  • Coexistence of significant concomitant illnesses, including heart disease, renal failure, hepatic disease, previous abdominal surgery, lactation, or pregnancy
  • Patients who had used probiotics and antibiotics in the past 12 weeks
  • Unwillingness to participate in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with concurrent Helicobacter pylori infection and small intestinal bacterial overgrowth (SIBO) represent a clinically challenging subgroup, often experiencing refractory gastrointestinal symptoms and diminished treatment responses. Current evidence indicates that individuals infected with H. pylori may related SIBO as a comorbidity; however, the synergistic effects of these conditions on gut ecosystem homeostasis remain poorly understood. To address this knowledge gap, we employed a dual-omics approach that combined shotgun metagenomic sequencing with liquid chromatography-mass spectrometry (LC-MS) metabolomic profiling. This methodology allowed for a comprehensive mapping of microbial community structures, including species-level taxonomy and functional pathways, as well as host-microbiota co-metabolism signatures in fecal samples.

The 4 groups in the trial

  • Group A

    H. pylori-positive and SIBO-positive group

    Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test

  • Group B

    H. pylori-negative and SIBO-positive group

    Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test

  • Group C

    H. pylori-positive and SIBO-negative group

    Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test

  • Group D

    H. pylori-negative and SIBO-negative group

    Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Characterization of Gut Microbiota and Metabolic Profiles in Patients With Helicobacter Pylori Infection and Small Intestinal Bacterial Overgrowth Based on Metagenomic and Metabolomic Analyses
Record updated
25 March 2026